PMID- 26329980
OWN - NLM
STAT- MEDLINE
DCOM- 20151125
LR  - 20150908
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 127
IP  - 7
DP  - 2015
TI  - Time-to-onset and -resolution of adverse events before/after atomoxetine 
      discontinuation in adult patients with ADHD.
PG  - 677-85
LID - 10.1080/00325481.2015.1083394 [doi]
AB  - BACKGROUND: Adults with attention-deficit/hyperactivity disorder treated with 
      atomoxetine were examined for time-to-onset and -resolution of common 
      treatment-emergent adverse events (TEAEs) and male sexual dysfunction, and for 
      changes in blood pressure (BP) and heart rate (HR) upon atomoxetine 
      discontinuation. METHODS: 12-week open-label atomoxetine (40-100 mg/day) was 
      followed by 12-week double-blind maintenance treatment (atomoxetine 80 or 100 
      mg/day). Responders were then randomized to atomoxetine (n = 266) or placebo (n = 
      258) for 25-week randomized withdrawal. Examined were (1) median time-to-onset 
      and -resolution of TEAEs during atomoxetine treatment, and (2) within group, 
      visitwise mean changes for sitting HR, systolic BP, and diastolic BP for the 
      postrandomization placebo group. RESULTS: Common adverse events (AEs) appeared 
      early, within week 1 of atomoxetine treatment. Some AEs resolve relatively 
      rapidly, whereas others have a more lingering course of resolution (including 
      male sexual side effects); median resolution times were 3 - 53 days. BP and HR 
      increases during atomoxetine treatment returned to baseline upon atomoxetine 
      discontinuation. CONCLUSION: Atomoxetine is associated with common AEs, with 3- 
      to 53-day median resolution times. TRIAL REGISTRATION: ClincialTrials.gov - 
      NCT00700427.
FAU - Upadhyaya, Himanshu
AU  - Upadhyaya H
AD  - a 1 Lilly Research Laboratories, Lilly Corporate Center , Indianapolis, IN, USA.
FAU - Tanaka, Yoko
AU  - Tanaka Y
FAU - Lipsius, Sarah
AU  - Lipsius S
FAU - Kryzhanovskaya, Ludmila A
AU  - Kryzhanovskaya LA
FAU - Lane, Jeannine R
AU  - Lane JR
FAU - Escobar, Rodrigo
AU  - Escobar R
FAU - Trzepacz, Paula T
AU  - Trzepacz PT
FAU - Allen, Albert J
AU  - Allen AJ
LA  - eng
SI  - ClinicalTrials.gov/NCT00700427
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150902
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Adrenergic Uptake Inhibitors)
RN  - 57WVB6I2W0 (Atomoxetine Hydrochloride)
SB  - IM
MH  - Adrenergic Uptake Inhibitors/administration & dosage/adverse effects
MH  - Adult
MH  - *Atomoxetine Hydrochloride/administration & dosage/adverse effects
MH  - Attention Deficit Disorder with Hyperactivity/*drug therapy
MH  - Blood Pressure/drug effects
MH  - *Cardiovascular Diseases/chemically induced/diagnosis/physiopathology
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - *Drug-Related Side Effects and Adverse 
      Reactions/diagnosis/etiology/physiopathology
MH  - *Erectile Dysfunction/chemically induced/diagnosis
MH  - Female
MH  - Heart Rate/drug effects
MH  - Humans
MH  - Male
MH  - Time Factors
MH  - Treatment Outcome
MH  - Withholding Treatment
OTO - NOTNLM
OT  - Atomoxetine
OT  - adult
OT  - adverse events
OT  - attention-deficit hyperactivity disorder
OT  - cardiovascular changes
OT  - male sexual dysfunction
EDAT- 2015/09/04 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/09/03 06:00
PHST- 2015/09/03 06:00 [entrez]
PHST- 2015/09/04 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - 10.1080/00325481.2015.1083394 [doi]
PST - ppublish
SO  - Postgrad Med. 2015;127(7):677-85. doi: 10.1080/00325481.2015.1083394. Epub 2015 
      Sep 2.